Press Releases
Search by Year
-
30 Oct 2024
SITES - Press Release
Third-Quarter 2024 Business Review
bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the nine months ended September 30, 2024: Consolidated sales amounted to €2,871 million, representing an organic growth of +10.3% at constant exchange rates and scope of consolidation.
-
15 Oct 2024
SITES - Press Release
bioMérieux receives CE-marking for VIDAS® VITAMIN B12 TOTAL, a blood test to measure total Vitamin B12 concentration
bioMérieux, a world leader in the field of in vitro diagnostics, announces the CE-marking of VIDAS® VITAMIN B12 TOTAL, an automated quantitative test for use on the VIDAS® immunoassay instruments, for the measurement of total Vitamin B12 concentration in human serum or plasma.
-
05 Sep 2024
SITES - Press Release
First-Half 2024 Results
Marcy l’Etoile (France), September 5th, 2024 – The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on September 4th under the chairmanship of Alexandre Mérieux and approved the consolidated financial statements for the six months ended June 30, 2024.
-
26 Jun 2024
SITES - Press Release
bioMérieux receives U.S. FDA Special 510(k) clearance and CLIA-waiver for its BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini
bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini has received U.S. Food and Drug Administration (FDA) Special 510(k) clearance and CLIA-waiver (Clinical Laboratory Improvement Amendments).
-
21 Jun 2024
bioMérieux receives US FDA 510(k) clearance for its AST System VITEK® REVEAL™
bioMérieux, a world leader in in vitro diagnostics, today announces that its VITEK® REVEAL™ AST System, reporting results directly from positive blood cultures, has received U.S. Food and Drug Administration (FDA) 510(k) clearance.
-
28 May 2024
SITES - Press Release
bioMérieux receives FDA 510(k) clearance of VIDAS® TBI (GFAP, UCH-L1), an innovative test to improve the assessment of patients with mild traumatic brain injury
bioMérieux, a world leader in the field of in vitro diagnostics, announces the U.S. FDA 510(k) clearance of VIDAS® TBI (GFAP, UCH-L1), a serum-based test to support the assessment of patients with mild traumatic brain injury (mTBI), including concussion.
-
23 May 2024
SITES - Press Release
Malawi Ministry of Health, bioMérieux, and Pfizer Form Country’s First Multisectoral Collaboration to Help Address Antimicrobial Resistance
The Malawi Ministry of Health, bioMérieux, and Pfizer today announced a collaboration to advance Malawi’s first multisectoral initiative which aims to build public sector antimicrobial stewardship (AMS) capacity in infection prevention and control, diagnostics, surveillance, and to guide the appropriate use of antibiotics.
-
09 Apr 2024
SITES - Press Release
bioMérieux presents its new 5-year strategic plan and its targets for profitable growth
bioMérieux, a world leader in the field in vitro diagnostics, is hosting today a Capital Markets Day in Paris. On this occasion, Pierre Boulud, Chief Executive Officer, together with members of the Executive Committee will present bioMérieux’s strategic plan, GO•28, the new chapter for the Company’s growth and development.
-
09 Apr 2024
SITES - Press Release
First-Quarter 2024 Business Review
bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31th, 2024.
-
05 Apr 2024
SITES - Press Release
bioMérieux and Mérieux NutriSciences partner with key food industry players to launch a new collaborative data-driven model
bioMérieux and Mérieux NutriSciences jointly announce the launch of a new data-driven Trusted Third Party initiative, built with a group of global food industry partners to foster safe industry collaboration as well as better anticipate and prevent food safety risks.